Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab

A case report

Norma Malavasi, Giovanni Ponti, Roberta Depenni, Federica Bertolini, Sandra Zironi, Gabriele Luppi, Pier Franco Conte

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.

Original languageEnglish
Article number35
JournalJournal of Hematology and Oncology
Volume2
DOIs
Publication statusPublished - 2009

Fingerprint

Colonic Neoplasms
Neoplasm Metastasis
Drug Therapy
Liver
Neoadjuvant Therapy
Documentation
Wound Healing
Referral and Consultation
Monoclonal Antibodies
Hemorrhage
Survival
Bevacizumab
Neoplasms
Therapeutics
Pathologists
Positron Emission Tomography Computed Tomography
Surgical Wound
Surgical Oncology

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research
  • Molecular Biology
  • Medicine(all)

Cite this

Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab : A case report. / Malavasi, Norma; Ponti, Giovanni; Depenni, Roberta; Bertolini, Federica; Zironi, Sandra; Luppi, Gabriele; Conte, Pier Franco.

In: Journal of Hematology and Oncology, Vol. 2, 35, 2009.

Research output: Contribution to journalArticle

@article{68f3f1cb9829415193f1905cd6f3b5ac,
title = "Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: A case report",
abstract = "The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.",
author = "Norma Malavasi and Giovanni Ponti and Roberta Depenni and Federica Bertolini and Sandra Zironi and Gabriele Luppi and Conte, {Pier Franco}",
year = "2009",
doi = "10.1186/1756-8722-2-35",
language = "English",
volume = "2",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central Ltd.",

}

TY - JOUR

T1 - Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab

T2 - A case report

AU - Malavasi, Norma

AU - Ponti, Giovanni

AU - Depenni, Roberta

AU - Bertolini, Federica

AU - Zironi, Sandra

AU - Luppi, Gabriele

AU - Conte, Pier Franco

PY - 2009

Y1 - 2009

N2 - The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.

AB - The complete pathological response after primary chemotherapy could represent an important prognostic factor in patients affected by colorectal liver metastases. In recent studies, increasing complete pathological response seems to be correlated with longer overall survival periods and it is recognized as an important prognostic factor in patients treated with pre-operative chemotherapy. The correlation of radiological information on residual neoplastic disease after neoadjuvant treatment, obtained with CT and PET, has to be evaluated; in fact the complete disappearance of liver metastasis on radiological imaging does not always mean a complete disappearance of tumor tissue on histological examination; when it is documented with surgical procedures and confirmed by pathologist's examination, we can consider the complete pathological response. In recent years the addition of monoclonal antibodies to conventional chemotherapy may further increase the proportion of patients referred for surgery; bevacizumab before surgery has been shown to be feasible and safe, although concerns still exist regarding possible post-surgical and wound healing complications or bleeding. The limitation of the radiologic assessment of response as a surrogate for pathological response is even more relevant when antiangiogenic treatments are used. Excellent responses to bevacizumab-containing regimens do occur and referral to surgical oncology is a crucial step for documentation of complete pathological response.

UR - http://www.scopus.com/inward/record.url?scp=69249230906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69249230906&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-2-35

DO - 10.1186/1756-8722-2-35

M3 - Article

VL - 2

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

M1 - 35

ER -